drugset / Trial / NCT01419600

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

NCT01419600

Phase 1 Completed 38 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of increasing single doses of AZD8683 administered via inhalation

Timeline

Start
2011-10
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8683 Unknown Other

Indications

No indication recorded.